IBDEI0QM ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13089,1,2,0)
 ;;=2^ANEURYSM,NON-AORTIC
 ;;^UTILITY(U,$J,358.3,13089,2)
 ;;=^7390
 ;;^UTILITY(U,$J,358.3,13090,0)
 ;;=710.3^^78^817^4
 ;;^UTILITY(U,$J,358.3,13090,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13090,1,1,0)
 ;;=1^710.3
 ;;^UTILITY(U,$J,358.3,13090,1,2,0)
 ;;=2^DERMATOMYOSITIS
 ;;^UTILITY(U,$J,358.3,13090,2)
 ;;=^33162
 ;;^UTILITY(U,$J,358.3,13091,0)
 ;;=446.5^^78^817^5
 ;;^UTILITY(U,$J,358.3,13091,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13091,1,1,0)
 ;;=1^446.5
 ;;^UTILITY(U,$J,358.3,13091,1,2,0)
 ;;=2^GIANT CELL ARTERITIS
 ;;^UTILITY(U,$J,358.3,13091,2)
 ;;=^117658
 ;;^UTILITY(U,$J,358.3,13092,0)
 ;;=446.20^^78^817^6
 ;;^UTILITY(U,$J,358.3,13092,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13092,1,1,0)
 ;;=1^446.20
 ;;^UTILITY(U,$J,358.3,13092,1,2,0)
 ;;=2^HYPERSENSITIVITY ANGIITIS, UNS
 ;;^UTILITY(U,$J,358.3,13092,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,13093,0)
 ;;=446.3^^78^817^7
 ;;^UTILITY(U,$J,358.3,13093,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13093,1,1,0)
 ;;=1^446.3
 ;;^UTILITY(U,$J,358.3,13093,1,2,0)
 ;;=2^LETHAL MIDLINE GRANULOMA
 ;;^UTILITY(U,$J,358.3,13093,2)
 ;;=^52905
 ;;^UTILITY(U,$J,358.3,13094,0)
 ;;=446.1^^78^817^8
 ;;^UTILITY(U,$J,358.3,13094,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13094,1,1,0)
 ;;=1^446.1
 ;;^UTILITY(U,$J,358.3,13094,1,2,0)
 ;;=2^MUCOCUTANEOUS LYMPH SYND (MCLS)
 ;;^UTILITY(U,$J,358.3,13094,2)
 ;;=^79494
 ;;^UTILITY(U,$J,358.3,13095,0)
 ;;=443.9^^78^817^12
 ;;^UTILITY(U,$J,358.3,13095,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13095,1,1,0)
 ;;=1^443.9
 ;;^UTILITY(U,$J,358.3,13095,1,2,0)
 ;;=2^PERIPH VASCULAR DIS NOS
 ;;^UTILITY(U,$J,358.3,13095,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,13096,0)
 ;;=446.0^^78^817^13
 ;;^UTILITY(U,$J,358.3,13096,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13096,1,1,0)
 ;;=1^446.0
 ;;^UTILITY(U,$J,358.3,13096,1,2,0)
 ;;=2^POLYARTERITIS NODOSA
 ;;^UTILITY(U,$J,358.3,13096,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,13097,0)
 ;;=710.4^^78^817^14
 ;;^UTILITY(U,$J,358.3,13097,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13097,1,1,0)
 ;;=1^710.4
 ;;^UTILITY(U,$J,358.3,13097,1,2,0)
 ;;=2^POLYMYOSITIS
 ;;^UTILITY(U,$J,358.3,13097,2)
 ;;=^186822
 ;;^UTILITY(U,$J,358.3,13098,0)
 ;;=452.^^78^817^15
 ;;^UTILITY(U,$J,358.3,13098,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13098,1,1,0)
 ;;=1^452.
 ;;^UTILITY(U,$J,358.3,13098,1,2,0)
 ;;=2^PORTAL VEIN THROMBOSIS
 ;;^UTILITY(U,$J,358.3,13098,2)
 ;;=^269815
 ;;^UTILITY(U,$J,358.3,13099,0)
 ;;=714.2^^78^817^16
 ;;^UTILITY(U,$J,358.3,13099,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13099,1,1,0)
 ;;=1^714.2
 ;;^UTILITY(U,$J,358.3,13099,1,2,0)
 ;;=2^RHEUMATOID ARTHRITIS,SYSTEMIC
 ;;^UTILITY(U,$J,358.3,13099,2)
 ;;=^272111
 ;;^UTILITY(U,$J,358.3,13100,0)
 ;;=135.^^78^817^17
 ;;^UTILITY(U,$J,358.3,13100,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13100,1,1,0)
 ;;=1^135.
 ;;^UTILITY(U,$J,358.3,13100,1,2,0)
 ;;=2^SARCOIDOSIS
 ;;^UTILITY(U,$J,358.3,13100,2)
 ;;=^107916
 ;;^UTILITY(U,$J,358.3,13101,0)
 ;;=710.0^^78^817^18
 ;;^UTILITY(U,$J,358.3,13101,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13101,1,1,0)
 ;;=1^710.0
 ;;^UTILITY(U,$J,358.3,13101,1,2,0)
 ;;=2^SYST LUPUS ERYTHEMATOSIS
 ;;^UTILITY(U,$J,358.3,13101,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,13102,0)
 ;;=710.1^^78^817^19
 ;;^UTILITY(U,$J,358.3,13102,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,13102,1,1,0)
 ;;=1^710.1
 ;;^UTILITY(U,$J,358.3,13102,1,2,0)
 ;;=2^SYSTEMIC SCLEROSIS
 ;;^UTILITY(U,$J,358.3,13102,2)
 ;;=^108590
 ;;^UTILITY(U,$J,358.3,13103,0)
 ;;=446.7^^78^817^20
 ;;^UTILITY(U,$J,358.3,13103,1,0)
 ;;=^358.31IA^2^2
